Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Pandion Therapeutics (NASDAQ:PAND) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Arrowhead Pharmaceuticals and Pandion Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Arrowhead Pharmaceuticals | 0 | 2 | 10 | 0 | 2.83 |
Pandion Therapeutics | 0 | 2 | 2 | 0 | 2.50 |
Arrowhead Pharmaceuticals currently has a consensus target price of $85.3077, suggesting a potential upside of 26.27%. Pandion Therapeutics has a consensus target price of $44.25, suggesting a potential downside of 26.31%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Pandion Therapeutics.
Profitability
This table compares Arrowhead Pharmaceuticals and Pandion Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Arrowhead Pharmaceuticals | -96.09% | -17.37% | -15.19% |
Pandion Therapeutics | N/A | N/A | N/A |
Earnings & Valuation
This table compares Arrowhead Pharmaceuticals and Pandion Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Arrowhead Pharmaceuticals | $87.99 million | 79.69 | $-84,550,000.00 | ($0.84) | -80.43 |
Pandion Therapeutics | $970,000.00 | 1,827.25 | $-21,880,000.00 | N/A | N/A |
Pandion Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals.
Institutional and Insider Ownership
65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 35.7% of Pandion Therapeutics shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Arrowhead Pharmaceuticals beats Pandion Therapeutics on 6 of the 11 factors compared between the two stocks.